Professor, Pediatrics, University of Tennessee Health Science Center College of Medicine
Hematology
Dr. Arthur W. Nienhuis, MD
|
|
Give Review
Arthur W. Nienhuis, MD practices Hematology. He researched medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a top medical university. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. He over the years received 2 awards: "Elected Member" and "Whos Who in Medicine and Healthcare". Dr. Arthur W. Nienhuis is a published physician. He published 39 publications, including: 'Long-term safety and efficacy of factor IX gene therapy in hemophilia B.'
Publications
- Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
- Development of gene therapy for blood disorders: an update.
- Pathophysiology and Clinical Manifestations of the β-Thalassemias.
- Development of gene therapy for thalassemia.
- Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B.
- Systemic Errors In Quantitative PCR Titration of Self-Complementary AAV Vectors and Improved Alternative Methods.
- Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins.
- Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities.
- Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
- Ninth Cooley's Anemia Symposium: summary and perspective.
- Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.
- A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythrobl...
- Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-t...
- Development of gene therapy for blood disorders.
- An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
- A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells.
- Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector.
- Assays to evaluate the genotoxicity of retroviral vectors.
- Genotoxicity of retroviral integration in hematopoietic cells.
- Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
- Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors.
- Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells.
- Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
- Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.
- Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulati...
- Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
- Current status of gene therapy for hemophilia.
- Development of gene therapy for hemoglobin disorders.
- The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromos...
- Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34 positive cells marked with a RD114 pseudotyped oncoretroviral vector.
- High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and mur...
- Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.
- Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation.
- Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells.
- Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood.
- Novel therapeutic approaches in sickle cell disease.
- Gene Therapy 2000.
Schools
D Geffen Sch Of MedUcla
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
David Geffen School of Medicine at UCLA
Hospital
-
University of Tennessee Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Michael G. Martin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moon J. Fenton, MD |
|
Dr. Jeffrey W. Allen, MD |
|
Dr. Peter W. Carter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey B. Niell, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul A. Ney, MD |
|
|
Dr. Rupert Handgretinger, MD |
|
|
Dr. Namratha R. Vontela, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephan W. Morris, MD |
|
Dr. Sonia M. Benn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jarvis D. Reed, MD
This Doctor is OpenDoctor Recommended.
|